pembrolizumab
merck
['kn-407', 'nsclc', 'sclc', 'pembro']
update of kn-407. with ~5 years follow-up, pembro (vs placebo) + chemo maintained an os + pfs benefit in advanced sq #nsclc regardless of pd-l1. 20% of patients alive / half without tumor recurrence after 5 yrs. still need improvement but it's impressive. #esmo22 
MD, PhD, Prof of Respiratory Medicine, Thoracic Oncology Specialist @CHUdeToulouse, @IUCTOncopoleICR; Researcher, INSERM @crctoncopole #LCSM ????? ?? ??